This technology is a method that integrates multi-omics data to accurately classify glioblastoma (GBM) tumor subtypes and identify functional pathways.
Unmet Need: Improved methods for classifying diverse and aggressive cancer types
Specific tumor subtypes have different disease progression and responsivity to treatment. Although transcriptomics is used to classify certain tumor subtypes in cancers such as breast cancer, classification methods have failed in accurately identify the subtypes of GBM and their respective prognoses and treatment options.
The Technology: Multi-omics approach for tumor subtype classification and improved prognosis
This technology integrates multi-omics (single cell RNA sequencing and bulk sequencing) to classify different subtypes of GBM tumors. Four functional states are identified: proliferative, mitochondrial, glycolytic/plurimetabolic, and neuronal. Subtype analysis reveals that mitochondrial GBM has the most optimal clinical outcome and responds favorably to oxidative phosphorylation inhibitors. This pipeline can be expanded beyond GBM to identify tumor subtypes from different cancers and its ability to characterize subtypes based on functional pathways will aid in identifying therapeutic targets to improve diagnoses and treatment strategies.
This technology has been tested using human high-grade glioma samples.
Applications:
- Multi-omics approach to classify tumor subtypes
- Characterization of subtypes to inform prognosis and possible treatments
- Identifying tumor-subtype-specific functional pathways for potential treatment targets
- Research approach for characterizing states and subtypes of diverse cancer types
Advantages:
- Unbiased approach for identifying tumor subtypes
- Identifies subtype-specific vulnerability to certain therapeutic inhibitors
- Can identify four major GBM functional states with differences in clinical outcome and response to treatment
- Adaptable to different cancer subtype classifications beyond GBM
Lead Inventor:
Anna Lasorella, M.D.
Patent Information:
Patent Status
Related Publications:
Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wißmann N, Botz M, Soyka SJ, Beretta CA, Pramatarov RL, Fankhauser L, Garofano L, Freudenberg A, Wagner J, Tanev DI, Ratliff M, Xie R, Kessler T, Hoffmann DC, Hai L, Dörflinger Y, Hoppe S, Yabo YA, Golebiewska A, Niclou SP, Sahm F, Lasorella A, Slowik M, Döring L, Iavarone A, Wick W, Kuner T, Winkler F. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022 Aug 4;185(16):2899-2917.e31.
Garofano L, Migliozzi S, Oh YT, D’Angelo F, Najac RD, Ko A, Frangaj B, Caruso FP, Yu K, Yuan J, Zhao W, Luisa Di Stefano A, Bielle F, Jiang T, Sims P, Suvà ML, Tang F, Su XD, Ceccarelli M, Sanson M, Lasorella A, Iavarone A. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021 Feb;2(2):141-156
Tech Ventures Reference:
